These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31813714)

  • 21. How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices.
    Sountoulides P; Mutomba WF; Bouras E; Lim J; Bourdoumis A; Jain A
    Urologia; 2020 Aug; 87(3):142-148. PubMed ID: 31959070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.
    Balakrishnan AS; Washington SL; Meng MV; Porten SP
    Clin Genitourin Cancer; 2019 Jun; 17(3):e461-e471. PubMed ID: 30799130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compliance With American Urological Association Guidelines for Nonmuscle Invasive Bladder Cancer Remains Poor: Assessing Factors Associated With Noncompliance and Survival in a Rural State.
    Tobert CM; Nepple KG; McDowell BD; Charlton ME; Mott SL; Gruca TS; Quast L; Erickson BA
    Urology; 2019 Oct; 132():150-155. PubMed ID: 31252002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
    J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
    Hendricksen K; Aziz A; Bes P; Chun FK; Dobruch J; Kluth LA; Gontero P; Necchi A; Noon AP; van Rhijn BWG; Rink M; Roghmann F; Rouprêt M; Seiler R; Shariat SF; Qvick B; Babjuk M; Xylinas E;
    Eur Urol Focus; 2019 Jul; 5(4):681-688. PubMed ID: 29074050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient Compliance With Maintenance Intravesical Therapy for Nonmuscle Invasive Bladder Cancer.
    Tapiero S; Helfand A; Kedar D; Yossepowitch O; Nadu A; Baniel J; Lifshitz D; Margel D
    Urology; 2018 Aug; 118():107-113. PubMed ID: 29792974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of non-muscle invasive bladder tumours by instillations of mitomycin C and BCG: a survey on French urologists by the French Urological Association].
    Descazeaud A; Mignard JP; Davin JL; Irani J
    Prog Urol; 2009 Oct; 19(9):624-31. PubMed ID: 19800553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).
    Jin YH; Zeng XT; Liu TZ; Bai ZM; Dou ZL; Ding DG; Fan ZL; Han P; Huang YR; Huang X; Li M; Li XD; Li YN; Li XH; Liang CZ; Liu JM; Ma HS; Qi J; Shi JQ; Wang J; Wang DL; Wang ZP; Wang YY; Wang YB; Wei Q; Xia HB; Xing JC; Yan SY; Zhang XP; Zheng GY; Xing NZ; He DL; Wang XH;
    Mil Med Res; 2022 Aug; 9(1):44. PubMed ID: 35978389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
    Marquette T; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Verde KL; Dermeche S; Gravis G; Pignot G
    Prog Urol; 2020 Jan; 30(1):35-40. PubMed ID: 31787540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).
    Neuzillet Y; Pradère B; Xylinas E; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Roumiguié M; Seisen T; Traxer O; Leon P; Roupret M
    Prog Urol; 2022 Nov; 32(15):1102-1140. PubMed ID: 36400479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A care bundle to improve perioperative mitomycin use in non-muscle-invasive bladder cancer.
    Batura D; Hashemzehi T; Colemeadow J
    Int Urol Nephrol; 2018 Jun; 50(6):1053-1059. PubMed ID: 29611146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
    Abufaraj M; Mostafid H; Shariat SF; Babjuk M
    Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy].
    Irani J
    Prog Urol; 2016 Nov; 26(14):860-864. PubMed ID: 27712914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.